Reply

Ophthalmology. 2018 Oct;125(10):e71-e72. doi: 10.1016/j.ophtha.2018.04.012.

Authors

Domenico Lepore¹, Marco H Ji², Graham Quinn³

Affiliations

¹ Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: [email protected].
² Department of Ophthalmology, Catholic University of the Sacred Heart, Rome, Italy.
³ Division of Pediatric Ophthalmology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

PMID: 30243342
DOI: 10.1016/j.ophtha.2018.04.012

No abstract available

Publication types

Letter
Comment

MeSH terms

Bevacizumab
Fluoresceins
Follow-Up Studies
Humans
Infant, Newborn
Intravitreal Injections
Retinopathy of Prematurity*

Substances

Fluoresceins
Bevacizumab